BioCentury
ARTICLE | Clinical News

Erivedge vismodegib: Additional Phase II data

May 28, 2012 7:00 AM UTC

Additional data from the open-label, international Phase II ERIVANCE BCC trial in 104 patients with inoperable advanced BCC showed that once-daily 150 mg oral vismodegib led to a 1-year survival rate of 77.3% in patients with metastatic BCC (n=33) and 93.1% in patients with locally advanced BCC (n=63). Data will be presented at the American Society of Clinical Oncology meeting in Chicago in June. ...